Clinical Perspectives

The Utility of Trastuzumab Monotherapy in HER2+ Breast Cancer

August 24, 2021

Extermann Treatment 640 Dr. Martine Extermann, left, treats a patient at Moffitt.

Martine Extermann, MD, PhD, program leader, Senior Adult Oncology Program

Older cancer patients who are reluctant to receive chemotherapy could be effectively treated with trastuzumab monotherapy without significantly compromising survival.

Patients who received trastuzumab alone had improved quality of life and fewer adverse effects compared with those who received trastuzumab plus chemotherapy, says Dr. Martine Extermann, MD, PhD, program leader of the Senior Adult Oncology Program at Moffitt Cancer Center.

Dr. Extermann discusses the findings in this video with OncLive

If you’d like to refer a patient to Moffitt Cancer Center, complete our online form or contact a physician liaison for assistance. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.